CASE COMMENTS: UNILATERAL PRACTICES – FRANCE – GENERICS – HEALTH AUTHORITIES – DENIGRATION

Generics: The French Competition Authority fines a pharmaceutical company for an abuse of its dominant position having delayed and then limited generic entry (Fentanyl transdermal patches)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. By Decision No 17-D-25 of 20 December 2017, the Competition Authority ("the Authority") sanctioned Janssen-Cilag, and its parent company Johnson & Johnson, to the tune of €25 million for first delaying and then limiting the development of generics of its drug, Durogesic. In so doing, the Authority is building up its case law on the defence of generic medicinal products a little further after several cases already concerning disparaging practices (see the Plavix case, Decision No 13-D-11 of 14 May 2013 concerning practices in the pharmaceutical sector, pts. 358 to 360, comm. F. Marty, Concurrences No. 3-2013, p. 85 and the case concerning Subutex,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Nicolas Zacharie, Anne Wachsmann, Generics: The French Competition Authority fines a pharmaceutical company for an abuse of its dominant position having delayed and then limited generic entry (Fentanyl transdermal patches), 20 December 2017, Concurrences N° 2-2018, Art. N° 86893, pp. 84 - 87

Visites 322

All reviews